Meisner Derek M 4

4 · Acumen Pharmaceuticals, Inc. · Filed Jan 28, 2026

AI-generated summary of this filing

Updated Jan 29, 2026

Acumen (ABOS) CLO Derek Meisner Exercises Options and Sells Shares

What Happened

Derek M. Meisner, Chief Legal Officer & Corporate Secretary of Acumen Pharmaceuticals (ticker: ABOS), exercised employee stock options and then sold the resulting shares. On Jan 26, 2026 he exercised 15,085 options at $1.85 ($27,907) and sold those 15,085 shares in the open market for a weighted average price of $3.00 (proceeds ~$45,263). On Jan 28, 2026 he exercised another 2,671 options at $1.85 ($4,941) and sold those 2,671 shares at a weighted average $3.00 (proceeds ~$8,017). Total exercised shares = 17,756 (exercise cost $32,848); total sale proceeds ≈ $53,280 (gross difference ≈ $20,432).

Key Details

Transaction dates and prices:
- 2026-01-26: Exercised 15,085 options at $1.85; sold 15,085 shares at weighted avg $3.00 (sales ranged $3.0000–$3.0100).
- 2026-01-28: Exercised 2,671 options at $1.85; sold 2,671 shares at weighted avg $3.00.
Transaction codes: M = option exercise/acquisition of shares; S = open-market sale.
Sales were automatic under a pre-established Rule 10b5-1 trading plan adopted March 29, 2025 (footnote F1).
Weighted-average sale price reported; the filer noted sales occurred in multiple trades between $3.0000–$3.0100 (footnote F2).
Vesting note for the options: they vest in 48 equal monthly installments over four years from grant, subject to continued service (footnote F3).
Shares owned after transaction: not specified in this Form 4.
Filing: Reported on Jan 28, 2026 for transactions on Jan 26 and Jan 28 — appears to be timely (no late filing noted).

Context

These filings show an option exercise immediately followed by open-market sales (common practice to cover exercise cost or diversify). The sales were conducted under a 10b5-1 plan, which typically means the trades were pre-scheduled and not spontaneous decisions. This is routine insider activity; it is factual reporting and not a statement of the insider’s views on the company’s prospects.

Form 4

Period: 2026-01-26

Chief Legal Officer & Corp Sec

Transactions

Exercise/Conversion
Common Stock
2026-01-26$1.85/sh+15,085$27,907→ 189,084 total
Sale
Common Stock
[F1][F2]
2026-01-26$3.00/sh−15,085$45,263→ 173,999 total
Exercise/Conversion
Common Stock
2026-01-28$1.85/sh+2,671$4,941→ 176,670 total
Sale
Common Stock
[F1][F2]
2026-01-28$3.00/sh−2,671$8,017→ 173,999 total
Exercise/Conversion
Employee Stock Option (right to buy)
[F3]
2026-01-26−15,085→ 85,215 total
Exercise: $1.85Exp: 2035-01-06→ Common Stock (15,085 underlying)
Exercise/Conversion
Employee Stock Option (right to buy)
[F3]
2026-01-28−2,671→ 82,544 total
Exercise: $1.85Exp: 2035-01-06→ Common Stock (2,671 underlying)

Footnotes (3)

[F1]The reported sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.
[F2]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.0000 to $3.0100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The shares subject to the employee stock option vest in 48 equal monthly installments starting on the date the option was granted, such that the option will be fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.

Signature

/s/ Derek Meisner|2026-01-28

1 file